Back to results
US 2016/0257676 A1Published application
Aminoisoquinoline Derivatives as Protein Kinase Inhibitors
AssigneeEternity Bioscience Inc.
InventorsMinsheng Zhang, Dong Liu, Biao Lu
Life of this patent
Estimating the term…
Abstract
The present invention provides novel aminoisoquinoline compounds as defined in the specification, compositions thereof use of these compounds as protein kinase inhibitors and as therapeutic agents for treatment of Raf kinase, in particular BRAFV600E kinase, related diseases or disorders, such as cancers. In addition, the invention also includes methods and processes for preparing these novel aminoisoquinoline compounds.
Claims44
A compound of formula (I):
- or a tautomer, a prodrug, or a pharmaceutically acceptable salt or solvate thereof, wherein:
- Y is hydrogen or C1-C4 alkyl, and Z is selected from hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, and —NRaRb;
- or alternatively, Y and Z are connected through a double bond (“Z═Y”) and are each independently CRy, CRz, or nitrogen (N), wherein Ry and Rz are each independently selected from hydrogen, halogen, hydroxyl, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, and C1-C4 haloalkoxy,
- X1, X2, X3, and X4 are each independently selected from hydrogen, halogen, hydroxyl, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, and C1-C4 haloalkoxy;
- R is selected from C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, 5- to 10-membered heterocyclyl, C3-C6 cycloalkyl-(C1-C4)-alkyl, C6-C10 aryl-(C1-C4)-alkyl, 5- to 10-membered heteroaryl-(C1-C4)-alkyl, and 5- to 10-membered heterocyclyl-(C1-C4)-alkyl, each optionally substituted with one, two, or three substituents independently selected from halogen, hydroxyl, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, —NRcRd, cyano, nitro, oxo, —C(O)R6, —C(O)OR7, and —C(O)NRcRd;
- Rx is hydrogen or C1-C4 alkyl, or alternatively, Rx and R, together with the nitrogen (N) and sulfur (S) atoms to which they are attached, form a five- or six-membered ring;
- R1 is hydrogen, C1-C6 alkyl, C6-C10 aryl, benzyl, —C(O)R6, or —C(O)OR7, each optionally substituted with one, two or three substituents independent selected from halogen, C1-C4 alkyl, haloalkyl, C1-C4 alkoxy, C1-C4 alkoxy, cyano, and NRaRb;
- R2, R3, R4, and R5 are each independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, and C1-C4 haloalkoxy;
- Ra and Rb are each independently selected from hydrogen, C1-C6 alkyl, benzyl, and —C(O)OR7, and
- R6 is hydrogen or C1-C4 alkyl;
- R7 is C1-C4 alkyl;
- and
- Rc and Rd are each independently hydrogen or C1-C4 alkyl.
10 more elements
42-45. (canceled)
(canceled)
Dependencies are inferred from the claim text.